The ink is barely dry, and already the legal vultures are circling. Tennessee’s FAIR Rx Act, a bill designed to stop Pharmacy Benefit Managers (PBMs) from owning pharmacies, just sailed through the state legislature. Sounds noble, right? A noble gesture that might just get smacked down like its predecessor in Arkansas. Because here’s the thing: the same powerful forces that tripped up Arkansas are already flexing their legal muscles. CVS Health and the Pharmaceutical Care Management Association (PCMA) are sharpening their knives, ready to slice this bill to ribbons with the same Commerce Clause arguments that worked before. And honestly? They might have a point.
A Familiar Tune, Different State
Arkansas tried this last year. A law banning PBMs from owning pharmacies. Big PBMs like CVS Caremark and Express Scripts, along with their trusty lobbying arm, the PCMA, sued. A judge agreed. The law, he said, trampled on the Commerce Clause, that old chestnut about states not messing with interstate business. Arkansas appealed. Now Tennessee, bless its heart, is taking a crack at it. The FAIR Rx Act. Passed with overwhelming support—24-9 in the Senate, 86-7 in the House. Governor Bill Lee is staring at it. Will he sign it? Or will he hand the PBMs another easy win? One legal expert, Eric Knowles of Frier Levitt, doesn’t mince words. “I do think that it may be an uphill battle to convince a court that it does not violate the Commerce Clause.” Translation: Get ready for déjà vu.
Minor Tweaks, Major Doubts
Sure, there are differences. Tennessee’s bill steers clear of federal contracts. A smart move, perhaps, considering the Arkansas law got tangled up with the federal TRICARE program. That was a big part of why that initial injunction landed. And Tennessee’s bill has a built-in two-year delay. July 1, 2028, is the magic date. Arkansas was aiming for January 1, 2026. A little breathing room. But will a few extra months change the fundamental legal calculus? Unlikely. The core issue remains: can a state dictate business practices to massive, multi-state corporations in a way that might unfairly burden them?
The Tennessee Pharmacists Association, naturally, is thrilled. They’ve seen firsthand the damage PBM vertical integration causes. Pharmacy closures. Reduced patient access. Shorter hours. And the kicker? PBMs paying their own affiliated pharmacies astronomical rates—up to 16,000% higher than others. It’s a racket. Pure and simple.
But the PBMs paint a grim picture. CVS warns of 25 MinuteClinic closures and 2,000 job losses. “It’s up to [Governor Lee] to ensure 1.5M+ Tennesseans can continue to be cared for by their trusted CVS pharmacist, 25 MinuteClinic retail medical clinics continue to provide acute and primary care for patients, and 2,000+ Tennesseans can keep their jobs,” spouted Amy Thibault, CVS’s corporate comms director. A veto, she argues, will protect communities. Optum Rx echoes the sentiment, claiming the law would “force some pharmacies to close and take options away from patients.” They trot out the usual suspects: patients with cancer, HIV, serious mental health needs—all supposedly dependent on specialized PBM-affiliated care. It’s a classic corporate scare tactic.
Is This Another Commerce Clause Catastrophe?
Here’s the real rub. The Commerce Clause isn’t some dusty relic; it’s a constitutional shield for national commerce. When a state law appears to favor in-state interests or unduly burden out-of-state businesses, courts tend to step in. Arkansas’s law, by preventing PBMs from owning pharmacies, was seen as a direct interference with how these national companies operate across state lines. Tennessee’s FAIR Rx Act does essentially the same thing, just with a slightly different preamble and a longer fuse.
The fact that Tennessee is in a different federal appeals district than Arkansas might offer a sliver of hope. Different judges, different interpretations? Perhaps. But the underlying legal precedent established by the Arkansas case looms large. It’s a tough hill to climb when the path has already been declared an uphill battle by legal experts.
Even if Governor Lee signs it, the PBMs will sue. That’s not a question of ‘if’, but ‘when’. They might wait until the implementation date, or they might strike immediately. Regardless, Tennessee’s legal team will be defending a bill that looks remarkably like one already struck down. The bipartisan votes in the legislature? Nice. A potential veto override? Possible. But neither will magically make the Commerce Clause disappear. This isn’t just about pharmacy profits; it’s about a fundamental legal question of state versus federal authority in regulating national industries. And the PBMs have a very, very deep legal war chest.
🧬 Related Insights
- Read more: The DTSA: Federalizing Trade Secrets, Federalizing Headaches?
- Read more: EU AI Act Slams Staffing Firms: Deployers, Not Just Vendors, on the Hook
Frequently Asked Questions
What is a PBM? Pharmacy Benefit Managers (PBMs) are intermediaries that negotiate drug prices between drug manufacturers, pharmacies, and health insurers. They manage prescription drug benefits for many health plans.
Will Tennessee’s FAIR Rx Act be enacted? It’s uncertain. The bill has passed the legislature and awaits the Governor’s decision. However, it faces significant legal challenges based on the Commerce Clause, similar to a law in Arkansas that was blocked by a judge.
Can states regulate PBMs? States can pass laws affecting PBMs, but these laws must comply with federal regulations and constitutional limits, such as the Commerce Clause, which restricts states from unduly burdening interstate commerce.
